HCW Biologics .

“This filing concerns the resale of up to 5.7M shares of common stock by selling stockholders. The company is a clinical-stage biopharmaceutical firm developing fusion immunotherapeutics.”

“HCW Biologics registered shares for resale from a $4.0 million private placement, which included $600,000 from insiders, providing crucial capital amidst financial distress and Nasdaq compliance issues, though it comes with significant pote…”more

“HCW Biologics Inc. received an extension from Nasdaq to regain compliance with the minimum $1 bid price rule, requiring demonstration by July 29, 2026, subject to conditions including a potential one-year Panel Monitor.”

“HCW Biologics Insider Purchases: HCW Biologics CEO Hing C. Wong acquires 113,879 common shares worth $160,499 HCW Biologics director Scott T. Garrett reports purchase of 177,936 shares for $249,501.12 HCW Biologics CFO Rebecca Byam acquires…”more

“HCW Biologics CEO Hing C. Wong purchased $160,000 of company stock in a private placement, signaling strong conviction despite recent financial challenges and a pending dilutive offering.”

“HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen.”